文献速递心脑血管急症

心肌梗死后低剂量秋水仙碱的疗效与安全性

Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction.
PubMed 文献 · N Engl J Med · 2019-11-16
一句话结论近期心肌梗死患者服用秋水仙碱0.5 mg每日一次,主要复合心血管终点风险低于安慰剂(HR 0.77)。

COLCOT随机双盲试验纳入心肌梗死后30天内患者4745例,随机分入秋水仙碱0.5 mg每日一次组(2366例)或安慰剂组(2379例),中位随访22.6个月。主要终点为心血管原因死亡、复苏成功的心脏骤停、心肌梗死、卒中或导致冠状动脉血运重建的紧急心绞痛住院的复合终点,秋水仙碱组5.5% vs 安慰剂组7.1%(HR 0.77;95%CI 0.61-0.96;P=0.02)。卒中(HR 0.26;95%CI 0.10-0.70)和导致血运重建的紧急心绞痛住院(HR 0.50;95%CI 0.31-0.81)风险降低,心血管死亡、复苏成功的心脏骤停和心肌梗死无显著差异。腹泻发生率两组无显著差异,肺炎作为严重不良事件秋水仙碱组0.9% vs 安慰剂组0.4%(P=0.03)。

要点

  • 近期心肌梗死(30天内)患者,秋水仙碱0.5 mg每日一次口服,主要复合心血管终点5.5% vs 安慰剂7.1%(HR 0.77;95%CI 0.61-0.96;P=0.02)。
  • 卒中风险秋水仙碱组低于安慰剂组(HR 0.26;95%CI 0.10-0.70),导致冠状动脉血运重建的紧急心绞痛住院风险亦降低(HR 0.50;95%CI 0.31-0.81)。
  • 心血管原因死亡(HR 0.84;95%CI 0.46-1.52)、复苏成功的心脏骤停(HR 0.83;95%CI 0.25-2.73)、心肌梗死(HR 0.91;95%CI 0.68-1.21)无显著差异。
  • 腹泻秋水仙碱组9.7% vs 安慰剂组8.9%(P=0.35),无显著差异;肺炎作为严重不良事件秋水仙碱组0.9% vs 安慰剂组0.4%(P=0.03)。

适用人群与场景

  • 心肌梗死后30天内招募的患者,随机分入秋水仙碱0.5 mg每日一次组(2366例)或安慰剂组(2379例)。

处置流程与药物剂量

  • 秋水仙碱0.5 mg每日一次口服,用于心肌梗死后30天内的患者,中位随访22.6个月。

研究设计与关键结果

  • 随机双盲试验,纳入4745例心肌梗死后30天内患者,秋水仙碱组2366例、安慰剂组2379例,中位随访22.6个月。
  • 主要复合终点(心血管原因死亡、复苏成功的心脏骤停、心肌梗死、卒中或导致冠状动脉血运重建的紧急心绞痛住院)秋水仙碱组5.5% vs 安慰剂组7.1%(HR 0.77;95%CI 0.61-0.96;P=0.02)。
  • 心血管原因死亡HR 0.84(95%CI 0.46-1.52);复苏成功的心脏骤停HR 0.83(95%CI 0.25-2.73);心肌梗死HR 0.91(95%CI 0.68-1.21);卒中HR 0.26(95%CI 0.10-0.70);导致冠状动脉血运重建的紧急心绞痛住院HR 0.50(95%CI 0.31-0.81)。
  • 腹泻秋水仙碱组9.7% vs 安慰剂组8.9%(P=0.35);肺炎作为严重不良事件秋水仙碱组0.9% vs 安慰剂组0.4%(P=0.03)。

证据类型、等级与局限

  • 证据类型:随机、双盲试验(COLCOT,ClinicalTrials.gov NCT02551094)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论:近期心肌梗死患者中,秋水仙碱0.5 mg每日一次较安慰剂显著降低缺血性心血管事件风险。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Experimental and clinical evidence supports the role of inflammation in atherosclerosis and its complications. Colchicine is an orally administered, potent antiinflammatory medication that is indicated for the treatment of gout and pericarditis.

METHODS: We performed a randomized, double-blind trial involving patients recruited within 30 days after a myocardial infarction. The patients were randomly assigned to receive either low-dose colchicine (0.5 mg once daily) or placebo. The primary efficacy end point was a composite of death from cardiovascular causes, resuscitated cardiac arrest, myocardial infarction, stroke, or urgent hospitalization for angina leading to coronary revascularization. The components of the primary end point and safety were also assessed.

RESULTS: A total of 4745 patients were enrolled; 2366 patients were assigned to the colchicine group, and 2379 to the placebo group. Patients were followed for a median of 22.6 months. The primary end point occurred in 5.5% of the patients in the colchicine group, as compared with 7.1% of those in the placebo group (hazard ratio, 0.77; 95% confidence interval [CI], 0.61 to 0.96; P = 0.02). The hazard ratios were 0.84 (95% CI, 0.46 to 1.52) for death from cardiovascular causes, 0.83 (95% CI, 0.25 to 2.73) for resuscitated cardiac arrest, 0.91 (95% CI, 0.68 to 1.21) for myocardial infarction, 0.26 (95% CI, 0.10 to 0.70) for stroke, and 0.50 (95% CI, 0.31 to 0.81) for urgent hospitalization for angina leading to coronary revascularization. Diarrhea was reported in 9.7% of the patients in the colchicine group and in 8.9% of those in the placebo group (P = 0.35). Pneumonia was reported as a serious adverse event in 0.9% of the patients in the colchicine group and in 0.4% of those in the placebo group (P = 0.03).

CONCLUSIONS: Among patients with a recent myocardial infarction, colchicine at a dose of 0.5 mg daily led to a significantly lower risk of ischemic cardiovascular events than placebo. (Funded by the Government of Quebec and others; COLCOT ClinicalTrials.gov number, NCT02551094.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Tardif JC, Kouz S, Waters DD, et al. Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. N Engl J Med. 2019. PMID: 31733140. doi:10.1056/NEJMoa1912388

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。